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ABSTRACT 
Vulvovaginal candidiasis (VVC) in HIV-infected (HIV+) women is a serious public 
health problem. However, little is known about the virulence mechanisms of vaginal Candida 
albicans from HIV+ women in the post-highly active antiretroviral therapy (HAART) era. 
Here, we report a comparative analysis of the expression of key virulence factors and genetic 
variability of 26 vaginal C. albicans strains isolated from HIV+ women undergoing HAART 
and 18 from HIV-uninfected (HIV-) women. In general, we observed that C. albicans from 
HIV+ women receiving HAART showed lower expression of virulence factors compared with 
C. albicans from HIV- women, except for the proteinase activity which is highly expressed. 
The results in HIV-women further suggest that virulence factors appear to be expressed in 
response to the yeast stress, in the presence of an adequate immune response. Furthermore, 
the RAPD results showed a high heterogeneity among isolates from both groups of women. 
These findings in HIV+ women using HAART will help to improve the monitoring of vaginal 
yeast infections and the quality of life of patients.
KEYWORDS: Vulvovaginal candidiasis. Candida albicans. HIV. Virulence. Genetic 
variability.
INTRODUCTION
Vulvovaginal candidiasis (VVC) is a disease caused by the abnormal growth of 
yeasts of the genus Candida in the mucosa of the female genital tract. The yeasts, 
in particular C. albicans, are well adapted to the human body and are capable of 
colonization with no signs of disease in conditions of physiological equilibrium1,2. 
However, under conditions that disrupt the delicate balance between the host and this 
commensal fungus, a parasitic relationship may occur, resulting in the development 
of infections termed candidiasis, including VVC2-4. Predisposing host factors, 
including immunosuppressive diseases such as HIV infection, are very important in 
the development of VVC4-6. The use of highly active antiretroviral therapy (HAART) 
has extended the life expectancy of HIV-infected individuals. However, some studies 
have reported that opportunistic infections remain a serious problem even in patients 
undergoing HAART5-7. Despite its importance, relatively little is known about the 
pathogenesis of VVC in HIV-infected women in the post-HAART era.
VVC is one of the most common fungal infections, frequently recurring in HIV 
infected women5. Although VVC is not known as an acquired immunodeficiency 
syndrome (AIDS)-defining condition, cases of VVC are often diagnosed among 
Zanni et al.
Rev Inst Med Trop São Paulo. 2017;59:e44Page 2 of 10
women with HIV-associated immunosuppression7. 
Symptoms of VVC are pruritus, discomfort, dyspareunia, 
and dysuria. Vulval infection presents as a morbilliform 
rash that may extend to the thighs. Vaginal infection is 
associated with white discharge and vaginal walls present 
with erythema and plaques. Although rarely or almost 
never resulting in systemic fungal infection or mortality, 
these lesions, if left untreated, contribute to the morbidity 
associated with HIV infection5.
C. albicans is the most common agent isolated from 
VVC in HIV-infected and uninfected women, appearing 
in 80-90% of cases in some reports1,6. The transformation 
from a harmless commensal to a virulent pathogen due to 
a dysfunctional host defense system involves an extensive 
repertoire of selectively expressed fungal virulence 
determinants8. Of these, adhesion capacity, biofilm 
development, cell surface hydrophobicity, morphological 
transition and production of hydrolytic enzymes by C. 
albicans are recognized essential steps in the process of 
Candida colonization and subsequent infection8-12. Genetic 
variability is related to C. albicans virulence due to the 
microevolution of strains within a particular species13. 
However, in spite of technological advances and the fact 
that VVC is a multifactorial disease, little is known on 
the mechanisms that make virulence factors and genetic 
variability contribute to the pathogenesis of vaginal C. 
albicans in HIV-infected women, so that their influence on 
the development of VVC remains unclear. 
Here, we report a comparative analysis of key virulence 
factors and genetic variability of vaginal C. albicans 




A total of 44 vaginal C. albicans isolates were previously 
collected, 26 from HIV-infected women (HIV+ group) and 
18 from uninfected women (HIV- group). All woman from 
the HIV+ group were undergoing HAART for less than 10 
years, provided by the Brazilian Health Minister and the 
Specialized Assistance Service for Sexually Transmitted 
Disease (SAS-STD)/AIDS in Maringá, Brazil. The 
therapeutic regimen adopted was the combination of at 
least an antiviral targeting the HIV protease. C. albicans 
isolates were separated into two groups according to 
clinical signs and symptoms presented by the women: 
colonization (COL) in cases with positive vaginal culture 
but no symptoms; and infection (INF) in those cases with 
positive vaginal culture and at least two symptoms of 
VVC (vaginal discharge, burning, itching, dysuria and/
or dyspareunia)14. All clinical isolates were identified by 
classical and biochemical methods15 confirmed by matrix-
assisted laser-desorption/ionization time-of-flight mass 
spectroscopy (MALDI TOF-MS). For MALDI TOF-MS, 
the yeasts were prepared and analyzed according to previous 
reports16,17 with a Microflex LT mass spectrometer (Bruker 
Daltonics) using the FlexControl software (version 3.0, 
Bruker Daltonics). The yeasts were stored in the culture 
collection of the Medical Mycology Laboratory of the State 
University of Maringá (UEM), Brazil. For each experiment, 
C. albicans isolates and C. albicans (ATCC 90028) from 
the American Type Culture Collection were subcultured on 
Sabouraud dextrose agar (SDA; Difco, Becton, Dickinson 
and Company, Sparks, Maryland, USA) overnight at 37 ºC. 
All virulence factors studied were assessed in triplicate and 
in three independent assays.
Proteinase activity assay
Proteinase activity was measured according to a 
previous report by Kuriyama et al.18, with modifications. 
C. albicans isolates were subcultured in yeast extract 
peptone dextrose broth (YEPD - Becton, Dickinson and 
Company, Sparks, Maryland, USA) at 37 °C for 24 h. 
The culture was washed, the concentration was adjusted 
to 1 × 106 yeast/ mL, and 500 µl of the suspension was 
added to 20 mL of yeast carbon base plus bovine serum 
albumin medium (YCB-BSA; Becton Dickinson, Oxford, 
UK) followed by incubation in a shaker at 37 °C for 48 h. 
The yeast concentrations were determined and then the 
solution was centrifuged. A volume (100 µL) of YCB-BSA 
culture supernatant was mixed with 400 µL of 0.1 M sodium 
citrate buffer (LabSynth, Diadema, São Paulo, Brazil) 
containing 1% bovine hemoglobin (Sigma, St. Louis, 
Missouri, USA). This mixture was incubated at 37°C for 
1 h. After incubation, 500 µL of 20% trichloroacetic acid 
(TCA; Sigma, St. Louis, Missouri, USA) were added and 
the mixture was incubated on ice for 1 h to precipitate 
any undigested protein. The precipitate was centrifuged 
and the peptide concentration from the supernatant was 
measured in a Nanodrop spectrophotometer (NanoDrop 
2000 UV-Vis Spectrophotometer, Thermo Scientific, 
Wilmington, Delaware, USA) at 280 nm. The control 
samples were inoculated into substrate broths that were 
immediately treated with TCA, without the 1 h incubation 
period. Proteinase activity was calculated based on the 
absorbance differences between samples and controls. One 
proteinase activity unit was defined as a 0.1 increase in the 
optical density (OD) at 280 nm/h. This value was related 
to the initial yeast/mL concentration to calculate the final 
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proteinase activity11. To confirm the proteinase activity, the 
culture supernatants were mixed with hemoglobin-sodium 
citrate buffer containing 50 mg/mL pepstatin A (Sigma, St. 
Louis, Missouri, USA). 
Cell surface hydrophobicity (CSH) assay
CSH was determined by testing microbial adhesion 
to hydrocarbons (MATH) according to Raut et al.12. 
C. albicans isolates were grown in YPD (Becton 
Dickinson, Oxford, UK) and resuspended in PBS to 
obtain a suspension with a final optical density (OD) 
of 0.5 at 620 nm evaluated by spectrometry (Quimis, 
Spectrophotometer Q7980RM, Diadema, SP, Brazil). A 
total of 100 µL of this suspension was distributed into 
96-well microplates. The plate was read at 620 nm using 
a microplate reader (Asys High Tech Expert Plus UV, 
Austria) and this value was designated as the initial OD of 
the yeast suspension. After the reading, 300 µL of n-octane 
were added to the wells, the samples were shaken for 
3 min., and the plate was allowed to stand for 15 min. to 
separate the phases. Subsequently, 10 µL of each lower 
aqueous phase was carefully removed and allocated to 
a new microplate well, and the final OD readings were 
obtained under the same conditions. The CSH percentage 
is given by the formula: % CSH = (1-OD of the final 
aqueous phase/OD of the initial yeast suspension) x 100. 
Adhesion and biofilm formation assays
The assays were performed according to Negri et al.19. 
Yeast cells were grown at 37 °C in a shaker at 120 rev/min 
for 18 h in Sabouraud dextrose broth (SDB; Difco, Becton, 
Dickinson and Company, Sparks, Maryland, USA). Yeast 
cells were washed with phosphate-buffer saline (PBS) and 
resuspended in RPMI 1640 (Sigma, Saint Louis, Missouri, 
USA) to a final concentration of 1 x 107 yeast/mL. Then, 
200 µL of suspension was added to each well of a 96-well 
plate and incubated for 2 h for adhesion assays or 24 h for 
biofilm formation assays. Yeast cell adhesion and biofilm 
formation were quantified using the crystal violet staining 
method. 
Scanning electron microscopy (SEM)
To examine yeast cell adhesion by SEM, 2 mL of the 
standardized cell suspension (1 x 107 yeast/mL in RPMI 
1640) was added to the wells of 24-well polystyrene plate 
and incubated for 2 h at 37 ºC in a shaker at 120 rev/min. 
After 2 h, the medium was aspirated, and non-adherent 
cells were removed by washing twice with PBS. Samples 
were fixed with 2.5% glutaraldehyde diluted in 0.1 M 
cacodylate buffer (Sigma, St. Louis, Missouri, USA) and 
dehydrated with an ascending series of alcohol solutions. 
Samples were kept in a desiccator until the bases of the 
wells were removed for analysis. Prior to observation, the 
bases of the wells were mounted onto aluminum stubs, 
sputter coated with gold and observed with a JEOL-JSM 
6360 LV scanning electron microscope (Jeol Ltd., Tokyo, 
Japan) at the Electron Microscopy Center, State University 
of Paraná, Maringá, Brazil. 
Germ tube formation and length
An inoculum was prepared in PBS according to the 
Nº 4 McFarland turbidity standard. This suspension was 
centrifuged at 1,170 g for 10 min. Then, the pellet was 
resuspended in RPMI 1640 medium containing fresh 
heat-inactivated human serum (1:1) and incubated for 3 h 
at 37 °C. The germ tubes were defined according to the 
description of Hammer et al.20 as a cell bearing a rounded 
outgrowth with a length greater than or equal to the diameter 
of the parent cell, not constricted at the base. Germ tubes 
were counted and measured with a light microscope (Nikon, 
TMD; Nippon Kogaku Inc.) equipped with a calibrated 
eyepiece graticule. Their frequency and length were 
determined in a blinded manner in 200 cells from each of 
the samples. The results were expressed as the average ± 
standard deviation (SD).
RAPD analysis
C. albicans isolates were analyzed according to Bonfim 
et al.21 using primers OPA-18 (5’-AGCTGACCGT-3’) and 
OPE-18 (5’-GGACTGCAGA-3’)22. The RAPD profiles 
were analyzed using the Bionumerics software version 4.6 
(Applied Maths, Carlsbad, CA, USA). For the determination 
of the size of fragments, we used a 100 bp molecular marker 
(Invitrogen, São Paulo, Brazil). The similarity was verified 
by the coefficient (SAB) between each pair of standards 
for A and B isolates and was calculated with the formula 
SAB = 2E / (2E + a + b), where E is the number of common 
bands in the patterns A and B; a is the number of bands with 
an A pattern and no correlated B patterns and b is the number 
of bands with a B pattern and no correlated A patterns. Based 
on the similarity matrix, the units were grouped using an 
unweighted pair-group method with arithmetical average 
(UPGMA). An SAB value of 100 indicates that the pattern of 
bands for line A is identical to B; values between 80 and 99 
represent very similar but not identical clinical isolates, and 
may suggest microevolution of a single strain; SAB values 
less than 80 represent independent lines23.
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Statistical analysis
Data distributions were expressed as the mean ± SD 
of three independent experiments, in triplicate. Significant 
differences among means were identified using the GraphPad 
Prism® 5.0 software and the Mann-Whitney and Bonferroni 
tests. Values of P < .05 were considered significant.
RESULTS
Antifungal susceptibility profile
Our previous study investigated antifungal activity in 
vitro for Fluconazole (FLU), Itraconazole (ITRA), Nystatin 
(NYST) and Amphotericin B, regarding all clinical isolates 
used in the present study. In general, C. albicans isolates 
showed no resistance to the antifungal agents tested. For 
the HIV+ group, 2 (7.7%) clinical isolates presented a dose-
dependent susceptibility (DDS) to FLU, 1 (3.9%) isolate to 
ITRA and 1 (3.9%) isolate to NYST. For the HIV- group, 7 
(38.9%) clinical isolates of C. albicans were DDS to NYST 
and 1 (5.5%) isolate to ITRA24. 
Proteinase activity
C. albicans isolates from the HIV+ group showed higher 
proteinase activity than C. albicans from the HIV- group 
(P < .0001) (Figure 1A). Furthermore, comparing the 
clinical groups (Figure 1B), C. albicans from the HIV+ 
INF group showed significantly greater proteinase activity 
than C. albicans from the HIV- INF group (P < .0001), 
and this activity was higher than 0.1 unit of proteinase 
activity/106 cells/mL.
CSH, adhesion capacity and biofilm formation
The clinical isolates showed similar CSH; this result 
was independent of HIV and clinical status (Figures 2A 
and 2B). According to the adhesion capacity and biofilm 
formation assays, all isolates demonstrated these 
abilities; however, in general, C. albicans from both 
groups were more efficient in the adhesion process than 
in biofilm formation (Figure 3). C. albicans isolates 
from the HIV+ group had lower capacities to adhere 
and to form biofilms than C. albicans isolates from 
the HIV- group (P < 0.0001) (Figures 3A and 3C). In 
regard to the adhesion capacity in the clinical groups, 
yeasts from the HIV- COL (2.21 to 3.03 abs/cm2) 
and INF (0.8 to 8.59 abs/cm2) groups showed higher 
adhesion values than yeasts from the HIV+ COL (0.71 
to 2.76 abs/cm2) and INF (1.07 to 3.56 abs/cm2) groups 
with P < 0.0001 (Figure 3B). C. albicans from HIV- COL 
(1.43 to 1.82 abs/cm2) and INF (0.252 to 2.66 abs/cm2) 
groups showed higher biofilm formation than yeasts from 
the HIV+ COL (0.16 to 0.99 abs/cm2) and INF (1.11 to 
0.73 abs/cm2) groups with P < 0.0001 (Figure 3B). 
Based on SEM, no morphological differences were 
observed in the adherence of C. albicans to the polystyrene 
microplate surface among isolates from the HIV+ and HIV- 
groups. In the HIV+ group, blastoconidia were attached 
to the microplate surface, isolated or in small clusters 
(Figures 4A and 4B). In the HIV- group, blastoconidia 
attached to the surface were isolated or in large clusters 
(Figure 4C and 4D). Initial extracellular matrix material 
was noted near the blastoconidia or with embedded 
microorganisms (Figures 4B and 4C). We also observed 
budding yeasts (Figures 4B and 4D).
Figure 1 - Proteinase activity (106 cells/ mL) of vaginal Candida albicans isolated from HIV positive (HIV+) and negative (HIV-) 
women overall and in clinical groups: A) Proteinase activity in HIV+ and HIV- groups; B) Proteinase activity in HIV+ and HIV- groups 
with colonization (COL) and infection (INF). Each bar represents the mean ± SD of the results from all isolates in each group (- three 
different experiments with samples tested in triplicate), *p<0.05 significant difference between HIV+ and HIV groups. ##p<0.05 
significant difference between HIV+INF and HIV-INF
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Figure 2 - Cell surface hydrophobicity (CSH) of vaginal Candida albicans isolated from HIV positive (HIV+) and negative (HIV-) 
women overall and in clinical groups: A) CSH (%) in HIV+ and HIV- groups; B) CSH (%) HIV+ and HIV- groups with colonization (COL) 
and infection (INF). Each bar represents the mean ± SD of the results from all isolates in each group (three different experiments 
with samples tested in triplicate).
Figure 3 - Adhesion and biofilm formation capacity (absorbance/cm2) of vaginal Candida albicans isolated from HIV positive (HIV+) 
and negative (HIV-) women overall and in clinical groups: A) Adhesion capacity in HIV+ and HIV- groups; B) Adhesion capacity 
in HIV+ and HIV- groups with colonization (COL) and infection (INF); C) Biofilm formation in HIV+ and HIV- groups; D) Biofilm 
formation in HIV+ and HIV- groups with colonization (COL) and infection (INF). Each bar represents the mean ± SD of the results 
from all isolates in each group (three different experiments with samples tested in triplicate), *p<0.05 significant difference between 
HIV+ and HIV- groups. #p<0.05 significant difference between HIV+COL and HIV-COL. ##p<0.05 significant difference between 
HIV+INF and HIV-INF.
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Germ tube formation capacity and length
C. albicans from the HIV- group demonstrated a higher 
germ tube formation capacity than C. albicans from the 
HIV+ group (P = .024) (Figure 5A). In the clinical groups, 
yeasts from the HIV- INF group showed a higher germ 
tube formation capacity than the HIV+ group (P = .0195) 
(Figure 5B). In contrast, the germ tube length was similar 
between the HIV + and HIV- groups and between the 
clinical groups (Figures 5C and 5D). 
Clinical isolate similarity by RAPD
The OPA-18 primer showed higher discriminatory 
power compared to the OPE-18 primer for all vaginal C. 
albicans isolates from the HIV+ and HIV- groups. For 
the HIV+ group, the OPA-18 primer identified 25 profiles 
with SAB values of 64.70 ± 18.12 (Figure 6A). Two groups 
(I and II) were formed with 36.6% similarity between 
them. Group I clustered 88.46% of the isolates with 66.6% 
similarity. Group II clustered 11.54% of isolates with 45% 
similarity. However, the OPE-18 primer only generated 7 
different profiles, with SAB values of 80.95 ± 18.71. The 
analysis clustered 92.2% of the isolates with approximately 
80.8% similarity (Figure 6B). For the HIV- group, 
primer OPA-18 identified 25 profiles with SAB values of 
75.11 ± 9.97 (Figure 6C). Two groups (I and II) were formed 
with 36.6% similarity between them. Group I clustered 
88.46% of the isolates with 66.6% similarity. Group II 
clustered 11.54% of isolates with 45% similarity. The 
OPE-18 primer only generated 7 different profiles, with a 
SAB value of 77.03 ± 16.53. The analysis clustered 92.2% of 
isolates with approximately 80.8% similarity (Figure 6D).
DISCUSSION
This study demonstrated that isolates of C. albicans 
from HIV+ women receiving HAART showed lower 
expression of virulence factors (except proteinase activity) 
than C. albicans from HIV- women and that expression of 
Figure 4 - Scanning electron photomicrographs showing vaginal Candida albicans from the HIV+ and HIV- groups adhered to the 
microplate surface after 2 h of contact: A) and B) HIV+ group adhesion showing yeasts in the blastoconidia form attached to the 
surface, isolated or in small clusters; C) and D) HIV- group adhesion showing several yeasts in the blastoconidia form attached to the 
surface, isolated or in large clusters. In A) and C) initial extracellular matrix material (red arrow) observed close to the blastoconidia 
or with microorganisms embedded. In B) and D) budding yeasts (blue arrows). Scale bars: A) and C), 10 µm; B) and D), 5 µm. 
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virulence factors was a yeast response to stress. Previous 
studies conducted in HIV+ women receiving HAART have 
indicated that vaginal colonization by yeasts is significantly 
increased in HIV+ women and is correlated with the loss 
of immunoprotective mechanisms25,26. However, little is 
known about the virulence factors of vaginal C. albicans 
from HIV+ women in the post-HAART era. To our 
knowledge, this is the first study describing these aspects 
comparing yeasts from HIV + and HIV- women.
The virulence factors of C. albicans have been defined 
as mechanisms that interact directly with host components-
contributing to the adherence, penetration and invasion of 
host tissues9-12. Proteinases are hydrolytic enzymes that 
contribute to the process of virulence and play an important 
role in the pathogenesis of VVC27. In this study, C. albicans 
from HIV+ women showed significantly higher proteinase 
activity than yeasts from HIV- women (Figure 1A). Similar 
results were found by De Bernardis et al.28 in C. albicans 
isolates from the oral cavity of HIV+ women showing 
increased proteinase activity compared with isolates from 
HIV- women. Although some reports have suggested that 
patients undergoing HAART with protease inhibitors (PI) 
show decreased proteinase activity of C. albicans29-31, our 
results showed the opposite, C. albicans isolates from HIV+ 
women had increased proteinase activity, and isolates from 
the HIV+/INF group showed two-fold greater proteinase 
activity than C. albicans from the HIV-/INF group. These 
findings may explain, at least partially, why opportunistic 
VVC infections remain a serious problem even in patients 
under HAART treatment5-7. However, these results did not 
clarify whether HAART with PI treatment had a persistent 
effect on fungal infection or carriage in vaginal mucosa. It 
has been suggested that proteinase production is a highly 
regulated process that is likely to reflect the complex 
transcriptional co-regulation with other virulence factors 
of C. albicans. The combination of virulence factors may 
promote the pathogenicity of C. albicans9,27. 
CSH contributes to interactions between cells and 
adjacent surfaces and seems to be an important factor in the 
adherence of C. albicans to inert surfaces12,32. Our results 
showed similar CSH in yeasts from HIV+ and HIV- women, 
irrespective of clinical groups. It has been observed that 
Figure 5 - Germ tube (GT) formation capacity (%) and length (µm) of vaginal Candida albicans isolated from HIV+ and HIV- women 
overall and in clinical groups: A) GT (%) in HIV+ and HIV- groups; B) GT in HIV+ and HIV- groups with colonization (COL) and 
infection (INF); C) GT length in HIV+ and HIV- groups; D) HIV+ and HIV- groups with colonization (COL) and infection (INF). Each 
bar represents the mean ± SD of the results from all isolates in each group (three different experiments with samples tested in 
triplicate). *p<0.05 significant difference between HIV + and HIV- groups.
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hydrophobic molecules are expressed to facilitate a stronger 
adhesion33,34. However, other important factors, such as the 
surface properties of both microorganisms and materials, 
as well as environmental factors, also increase or decrease 
the adhesion capacity3,9,11,32.
C. albicans from HIV+ women had a lower capacity 
for adhesion and biofilm formation than C. albicans from 
HIV- women, in both clinical groups (Figures 3A and 3C). 
Adhesion generally involves the formation of blastoconidia, 
the occasional formation of hyphae and an initial production 
of extracellular matrix, which was observed by SEM in 
this study, confirming results observed in other studies35. 
However, the incubation period is a critical factor, and 
prolonged periods of time allow for the formation of 
complex biofilms, with blastoconidia and hyphae-like 
forms, as demonstrated in C. albicans by Paiva et al.35.
While adhesion capacity is important for tissue 
infection, biofilm formation is an important process that 
helps to maintain the yeast on natural host surfaces10. When 
Candida forms biofilms, it displays phenotypic properties 
that are different from those in planktonic growth, such 
as enhanced resistance to antifungals and neutrophils and 
altered gene expression, allowing the yeast to remain in a 
hostile environment where it is often in competition with 
other microorganisms, in addition to the local response of the 
host8,10. Mane et al.8 showed results that differed from ours 
in yeast isolated from the oral cavity of HIV+ individuals; 
the yeast showed increased biofilm formation. This is an 
important difference of yeasts from the vaginal mucosa of 
HIV+ women and deserves further study. Furthermore, oral 
environments promote increased development of biofilms 
due to the variability of oral hygiene, salivation and greater 
variability of the local microbiota36.
Both blastoconidia and hyphal cells of C. albicans are 
found in infected host tissues, and it is widely believed that 
hyphal formation is important for its invasive properties 
and is associated with adhesion and invasion of tissues12. 
However, our results showed less germ tube formation in 
C. albicans isolates from HIV+ compared to HIV- women, 
although the germ tube length was similar in both groups. 
These transitions between yeast, pseudohyphal and hyphal 
growth forms contribute to the virulence of C. albicans, 
which interacts directly with host components as a response 
to stress25,26. These results suggest that strains submitted 
to lower levels of stress had attenuated virulence factors 
and strains that suffered greater stress had enhanced 
pathogenicity against the host. According to Brown et al.25, 
stress leads to an adaptive response of the host although it 
is not clear whether this genetic adaptation is observed both 
in vivo and in vitro. 
Clustering analysis using the RAPD method showed 
that, in general, the isolates from HIV+ and HIV- women 
showed a high degree of heterogeneity. The range of mean 
SAB values was less than 80% in all the primers examined, 
suggesting the presence of independent strains and 
confirming the results of Chong et al.23. Low similarity 
among vaginal isolates has been reported by other authors37. 
No correlation was observed between the clustering and 
virulence factors analyzed. These results demonstrate that 
vaginal colonization or VVC varies among individuals and 
ranges between strain maintenance, strain microevolution 
and strain replacement; the major scenario is the strain 
maintenance with microevolution23. 
The results of this study suggest that C. albicans 
virulence factors from HIV+ and HIV- individuals are 
expressed in response to yeast stress. Recent studies 
Figure 6 - Dendrogram generated by RAPD analysis of vaginal 
Candida albicans isolated from HIV + and HIV- women using 
the UPGMA (unweighted pair-group method with arithmetical 
average) grouping, with SAB calculated by the coefficient of 
Dice: A) and C) Yeast dendrograms using the OPA-18 primer; 
B) and D) Yeast dendrograms were constructed using the OPE-
18 primer results. The numbers indicated on the right side of 
dendrograms represent the registration of each yeast in the 
culture collection of the Medical Mycology Laboratory of the 
State University of Paraná, Maringá (UEM), Brazil. 
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indicated that heterogeneous behaviors in specific host 
niches lead to different genetic adaptations25. Moreover, 
virulence factors should never have been considered 
independent of the host’s defenses, and the clinical course 
of a disease often depends on the interaction of virulence 
factors with the host’s response. It is known that the integrity 
of the immune system (physical and chemical attributes) 
is able to stimulate the virulence of the microorganisms38. 
Additionally, previous results from our group24 showed that 
clinical isolates from both groups-did not have an antifungal 
resistance profile, suggesting that the presence of yeast in 
the vaginal environment of the studied women is in fact 
related to virulence factors.
In summary, our study demonstrated that isolates of 
C. albicans from HIV+ women undergoing HAART had 
lower expression of virulence factors than isolates from 
HIV- women, with the exception of proteinases, which 
were highly expressed. The study further demonstrated that 
virulence factors are expressed according to the level of 
stress to which the yeast was exposed. These findings will 
allow the better monitoring of vaginal yeasts infections in 
HIV-infected women under HAART treatment which will 
improve the quality of life of patients.
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